MTOR and cancer: On the contrary, pharmacological inhibition of the PI3K/AKT/mTOR pathway may result in the upregulation of Cyclin D1 or other cell cycle regulatory proteins, effectively enabling cancer cells to circumvent the intended therapeutic effects [32,33].